CYTORI THERAPEUTICS, INC. (NASDAQ:CYTX) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01Entry into a Material Definitive Agreement

On February 27, 2017, Cytori Therapeutics, Inc. (the Company)
entered into a Lease Agreement (the Lease) with 6262 Lusk
Investors LLC, a California limited liability company (Landlord),
for approximately 29,499 square feet of office space for the
Companys corporate headquarters in San Diego, California. The
initial term of the Lease is sixty-three (63) months, and may be
extended upon mutual agreement of the Company and the
Landlord.The Lease is scheduled to commence on November 1, 2017
date, unless the premises are earlier occupied by the Company or
the commencement date is delayed to allow for substantial
completion of tenant improvements.

Under the Lease, the Company will be obligated to pay base rent
as follows:

In addition to the base rent, the Company will also be obligated
under the Lease to make certain payments for operating expenses,
property taxes, insurance, insurance deductibles and other
amounts.

In connection with the Lease, the Company issued a letter of
credit, or Letter of Credit, in favor of the Landlord in the
initial principal amount of $126,845.00, which Letter of Credit
will increase to $253,690.00 on June 1, 2017, and to $500,000.00
on the commencement date.The Letter of Credit will remain in
effect for the term of the Lease.

The Company has agreed to customary indemnifications of the
Landlord and its affiliates arising out of the Companys use of
the rented premises, breaches of the Companys obligations under
the Lease and similar matters (except to the extent arising out
of the Landlords gross negligence or willful misconduct).

The foregoing description of the Lease is a summary, is not
complete, and is qualified in its entirety by the terms and
conditions of the actual Lease. The Company intends to file the
Lease with the Companys Annual Report on Form 10-K for the fiscal
year ended December 31, 2016.

About CYTORI THERAPEUTICS, INC. (NASDAQ:CYTX)

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

CYTORI THERAPEUTICS, INC. (NASDAQ:CYTX) Recent Trading Information

CYTORI THERAPEUTICS, INC. (NASDAQ:CYTX) closed its last trading session down -0.07 at 1.59 with 175,865 shares trading hands.